These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders. Ward LM, Ma J, Robinson ME, Scharke M, Ho J, Houghton K, Huber A, Scuccimarri R, Barsalou J, Roth J, Shenouda N, Matzinger MA, Lentle B, Jaremko JL, Koujok K, Watanabe Duffy K, Stein R, Sbrocchi AM, Rodd C, Miettunen PM, LeBlanc CMA, Larche M, Jurencak R, Cummings EA, Couch R, Cabral DA, Atkinson S, Alos N, Sykes E, Konji VN, Rauch F, Siminoski K, Lang B. J Clin Endocrinol Metab; 2021 Nov 19; 106(12):e5195-e5207. PubMed ID: 34232311 [Abstract] [Full Text] [Related]
3. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R, Miettunen PM, Roth J, Atkinson SA, Couch R, Cummings EA, Dent PB, Ellsworth J, Hay J, Houghton K, Jurencak R, Larché M, LeBlanc C, Oen K, Saint-Cyr C, Stein R, Stephure D, Taback S, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Arthritis Care Res (Hoboken); 2012 Jan 19; 64(1):122-31. PubMed ID: 22213727 [Abstract] [Full Text] [Related]
4. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Arthritis Care Res (Hoboken); 2010 Apr 19; 62(4):516-26. PubMed ID: 20391507 [Abstract] [Full Text] [Related]
7. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, Abish S, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J, Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) ConsortiumCanadian Pediatric Bone Health Working Group, Ottawa, ON, Canada.. J Bone Miner Res; 2018 Aug 19; 33(8):1435-1443. PubMed ID: 29786884 [Abstract] [Full Text] [Related]
10. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Hoes JN, Jacobs JW, Hulsmans HM, De Nijs RN, Lems WF, Bruyn GA, Geusens PP, Bijlsma JW. Clin Exp Rheumatol; 2010 Aug 19; 28(3):354-9. PubMed ID: 20406615 [Abstract] [Full Text] [Related]
11. Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. Sugiyama T, Suzuki S, Yoshida T, Suyama K, Tanaka T, Sueishi M, Tatsuno I. Gend Med; 2010 Jun 19; 7(3):218-29. PubMed ID: 20638627 [Abstract] [Full Text] [Related]
12. Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids. Harrington J, Holmyard D, Silverman E, Sochett E, Grynpas M. Pediatr Rheumatol Online J; 2016 Nov 10; 14(1):58. PubMed ID: 27832795 [Abstract] [Full Text] [Related]
13. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. Rentero ML, Amigo E, Chozas N, Fernández Prada M, Silva-Fernández L, Abad Hernandez MA, Rodriguez Barrera JM, del Pino-Montes J, GHDP study group. BMC Musculoskelet Disord; 2015 Oct 15; 16():300. PubMed ID: 26472426 [Abstract] [Full Text] [Related]
14. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. Alos N, Grant RM, Ramsay T, Halton J, Cummings EA, Miettunen PM, Abish S, Atkinson S, Barr R, Cabral DA, Cairney E, Couch R, Dix DB, Fernandez CV, Hay J, Israels S, Laverdière C, Lentle B, Lewis V, Matzinger M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Wilson B, Williams K, Rauch F, Siminoski K, Ward LM. J Clin Oncol; 2012 Aug 01; 30(22):2760-7. PubMed ID: 22734031 [Abstract] [Full Text] [Related]
17. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM, Canadian STOPP Consortium. Osteoporos Int; 2012 Feb 01; 23(2):751-60. PubMed ID: 21494860 [Abstract] [Full Text] [Related]
18. The impact of underlying disease on fracture risk and bone mineral density in children with rheumatic disorders: A review of current literature. Huber AM, Ward LM. Semin Arthritis Rheum; 2016 Aug 01; 46(1):49-63. PubMed ID: 27020068 [Abstract] [Full Text] [Related]